CEP Adult Major Depressive Disorder (MDD) Tool PDF

Section: A B C D E F G Resources References Treatment of Adult Major...

Section: A B C D E F G Resources References Treatment of Adult Major Depressive Disorder (MDD) Tool This tool is designed to support primary care providers in the treatment of adult patients (≥ 18 years) who have major depressive disorder (MDD). MDD is the most prevalent depressive disorder, and approximately 7% of Canadians meet the diagnostic criteria every year.1,2 The treatment of MDD involves psychotherapy and/or pharmacotherapy. Providers should work with patients to create a treatment plan together using providers’ clinical expertise and keeping in mind the patient’s preferences, as well as the practicality, feasibility, availability and affordability of treatment. TABLE OF CONTENTS pg. 1 Section A: Overview of MDD pathway pg. 6 Section E: Complementary and alternative medicine pg. 2 Section B: Assessing suicidality and managing pg. 7 Section F: Follow-up and monitoring suicide-related behaviour pg. 9 Section G: Special patient populations pg. 3 Section C: Psychotherapy options pg. 10 Resources pg.3 Section D: Pharmacotherapy management SECTION A: Overview of MDD pathway Patient has suspected depression Talking Points It is important to provide your patient with non-judgmental care (e.g. “Being Consider unexpected life events (e.g. death in the family, diagnosed with depression is nothing to be ashamed of, it is very common and change in family status, financial crisis). Consider special many adults are diagnosed with it every year”) patient populations. Don’t use clinical/psychiatric language (e.g. “mental health,” “psychiatric,” and/or “maladaptive”) unless the patient uses these terms first Use understandable language for cognitive distortions (e.g. “assumption” Screen using the PHQ-93 screen patient for depression which covers many cognitive distortions, “thought trap” instead of rumination) Use positive language, and maintain a focus on your patient’s strengths Avoid stigmatizing labels (e.g. “abnormal”, “unusual”) Talk about symptoms instead of disorders/diagnoses PHQ-9 Scores of > 5 PHQ-9 (a score of 0-4 does not meet Mild Moderate Severe criteria for MDD) (score 5-9) (score 10-14) (score >14) Conduct Diagnostic Work-up Treat the cause of secondary Yes Rule out causes of secondary MDD and other disorders MDD by conducting tests for B-12 deficiency, CBC, folic Set EMR reminders Conduct Risk Assessment No acid deficiency, corticosteroid to follow-up at Is the patient at immediate risk medication, hypothyroidism and the patient’s next of harm to self and/or others? Use syphilis appointment to see the CEP’s Keeping Your Patients Rule out comorbid alcohol5 and Confirm the diagnosis of MDD if their PHQ-9 score Safe: A Guide to Primary Care No substance use disorder6 using the DSM-V criteria* changes. Management of Mental Health Rule out bipolar disorder7 and Addictions-related Risks and Assess if patient has a sleeping Functional Impairments4 tool to disorder8 assess the patient. Rule out other chronic diseases Yes Create a safety plan with lower risk patients. Consult the Asessing suicdality and managing suicide-related behaviour section. Proceed with the following sections: Psychotherapy options, Advise your patient, their family, caregivers and friends to Pharmacotherapy management , Complementary and alternatives medicine. call 911 or get them to the nearest Emergency Department Consult the Asessing suicdality and managing suicide- related behaviour section for more information. Refer to Follow-up and Monitoring * A DSM-V score of > 5 with symptoms during the same two week period that are a change from the previous functioning. Depressed Mood (Q1) and/or loss of interest/pleasure (Q2) must be present9 November 2019 cep.health/major-depressive-disorder Page 1 of 11  Section: A B C D E F G Resources References SECTION B: Assessing suicidality and managing suicide-related behaviour Suicidal thoughts, plans, and attempts are very common among people with MDD.10 Every clinical encounter with a patient that has MDD should include an assessment of suicide risk.10 Assess if a patient is at risk of suicide or developing suicidal thoughts by using the Columbia-Suicide Severity Rating Scale (C-SSRS) In case of an emergency: Talking Points Advise your patient, their family, caregivers and friends to call 911 or go to the Emergency Department Use active listening: involves receiving a message, processing it, and sending it back. Consult the CEP’s Keeping Your Patients Safe on how to complete a Remember that your patient is the expert on their Form 1, if you believe that your patient is at immediate risk of harming own experience. themselves or others Schedule periodic follow-up appointments to track your patient’s progress and assess their well-being Monitor the presence and strength of the patients’ protective factors4 Create a safety plan with lower-risk patients Help your patient identify the nearest distress centre11 Basic components of a safety plan Work with your patient to develop a safety plan that they can use when in crisis. Safety plan12 1. Recognize warning signs that are proximal to an impending suicidal crisis. Having a safety plan in place is important for both patients 2. Identify and employ internal coping strategies without needing to contact another person. and providers as it: 3. Use contacts with people as a means of distraction from suicidal thoughts and Facilitates honest communication between patient and urges (e.g. going to healthy social settings without discussing suicidal thoughts). provider 4. Contact family members or friends who may help to resolve a crisis and with Establishes a collaborative relationship between patient whom suicidality can be discussed. and provider 5. Contact mental health professionals or agencies. Facilitate the patient’s active involvement 6. Reduce the potential use of lethal means. Enhances patient’s commitment to treatment See Keeping Your Patients Safe and Portico for more information Click here to access a safety plan template SECTION C: Psychotherapy options When selecting a specific type of psychotherapy consider the patient’s Talking Points treatment goals and preferences (e.g. group or individual therapy), whether the Set realistic expectations when initiating treatment patient has had a prior positive response to “If you stick to your treatment, you should feel better than you do now. It’s also okay if you don’t psychotherapy treatment and if providers feel better right away. We can help to eventually make your life feel easier.” skilled in the preferred psychotherapy “Recovery will have its ups and downs.” approach are available. “People who stick to their treatment plan are the ones who see the most improvement over time. So, we are going to work together to make sure that happens.” The stepped care approach: Start with the least intrusive form of Provide your patient with adequate support care and progress to more intensive “Depression is a common experience, you’re not alone in this. It takes a lot of strength to seek care if needed. support.” First-line psychotherapy options Mild to Moderate 13,14 Severe 13,14 Cognitive-behavioral therapy (CBT) It is suggested to offer a combination of psychotherapy and pharmacotherapy for patients with the following forms/presentations Interpersonal psychotherapy (IPT) of MDD Behavioral therapy/behavioral activation (BT/BA) Severe (i.e. PHQ-9 >20) Acceptance and commitment therapy (ACT) Chronic (duration greater than two years) Mindfulness-based cognitive therapy (MBCT) Recurrent (with three or more episodes) Problem-solving therapy (PST) For additional help, consult specialists across the province to provide the Refer to ConnexOntario for Addiction, Mental Health, and Problem best care possible for patients with complex MDD at OTN eConsult15 and Gambling Treatment Services. the Collaborative Mental Health Network (CMHN).16 For more details on psychotherapy options and second-line treatments please see Appendix A November 2019 cep.health/major-depressive-disorder Page 2 of 11  Section: A B C D E F G Resources References SECTION D: Pharmacotherapy management The medications listed below (organized by drug class), are all equal in efficacy and in evidence.17,18 The selection of a first-line antidepressant is dependent on the following considerations: Patient: Medication: Clinical features and dimensions (refer to Appendix F) Comparative efficacy Comorbid conditions Comparative tolerability warnings, contraindications and precautions Response and side effects of previous use of antidepressants Potential interactions with other medications (refer to Appendix E) Patient preference Simplicity of use Cost and availability First-line antidepressants 17,19 Drug Class Antidepressant Formulations Dosage Side Effects Warnings, Contraindications and Precautions DAA Bupropion 100 mg and 150 SR formulation (doses >150 Agitation Contraindicated in seizure disorders mg tablet mg/day PO should be given Insomnia Contraindications for any patient Product monograph in divided doses): Anorexia undergoing abrupt discontinuation of for SR Initial: 150 mg/day PO alcohol49 Usual: 150–300 mg/day PO Product monograph There is an increased risk of seizure High: 375–450 mg/day PO for XL in patients with anorexia nervosa or XL formulation (given once bulimia49 daily): Initial: 150 mg/day PO Contraindications for any patient Usual: 150–300 mg/day PO undergoing abrupt discontinuation High: 450 mg/day PO of alcohol SM Vortioxetine 5 mg, 10 mg, Initial: 5–10 mg daily PO Nausea 15 mg, 20 mg Usual: 10–20 mg daily PO Constipation Product monograph tablet Vomiting Transient symptoms associated with abrupt discontinuation include: Headache Increased dreaming Mood swings Muscle tension Vertigo Rhinorrhea SNRI Desvenlafaxine 50 and 100 Initial: 50 mg daily PO Nausea mg extended- Usual: 50 mg daily PO Sleep disturbance Product monograph release tablet High: 100 mg daily PO Drowsiness Nervousness Dizziness Dry mouth Duloxetine 30 mg and 60 Initial: 60 mg daily PO Nausea Do not use in patients with severe mg delayed- Usual: 60 mg daily PO Drowsiness renal impairment (ClCr 25% Refer to first-line adjunctive improvement)* medications for options. Optimize by increasing dose if not at maximum dosage (every 2 If symptoms do not improve, weeks) switch medications. No response (